Wolverine Stack (BPC-157 + TB-500) Dosage & Mixing Guide

Wolverine Stack (BPC-157 + TB-500)

The Wolverine Stack combines BPC-157 and TB-500 in a two-peptide research-use framework. The individual compounds are associated with different areas of tissue-repair and regenerative research, but the combined Wolverine Stack has not been clinically validated as a standardized human treatment protocol.

How It Works

BPC-157 → Preclinical Tissue-Repair Signaling
TB-500 → Cell-Migration + Repair-Signaling Research
Combined → Complementary Multi-Pathway Research Framework

BPC-157 and TB-500 are commonly paired in recovery-focused research discussions because they are associated with different repair pathways. However, controlled human trials have not established that combining the two produces faster or better healing than either compound alone.

Blended Vial Protocol (Simple)

5 mg BPC-157 + 5 mg TB-500 → 3.0 mL BAC Water → 1 unit = 16.7 mcg of each peptide

Blended Vial Setup

Blend5 mg BPC-157 + 5 mg TB-500

Water3.0 mL

Concentration1.67 mg/mL each

Conversion1 unit = 16.7 mcg BPC-157 + 16.7 mcg TB-500

Combined1 unit = 33.3 mcg total

Weeks 1–2

Starting Phase

Dose250 mcg of each peptide daily

Combined Total500 mcg total

Units15 units total

Volume0.15 mL

Weeks 3–4

Full Support Phase

Dose500 mcg of each peptide daily

Combined Total1,000 mcg total

Units30 units total

Volume0.30 mL

Weeks 5–8

Maintenance Framework

Dose500 mcg of each peptide daily

Combined Total1,000 mcg total

Units30 units total

Volume0.30 mL

Why use blended?

Simple Structure

This is the simplest version. Both peptides are delivered together in one syringe with one daily draw.

Best For

Useful when simplicity, one-syringe convenience, and straightforward blend math are the priority.

Separate Vials Protocol (Flexible)

BPC-157 = Daily Repair Signaling → TB-500 = Less Frequent Systemic Support → More Flexible Dosing Logic

Separate Vials Setup

Based on 10 mg vials for each peptide

BPC-15710 mg vial + 3.0 mL BAC water

TB-50010 mg vial + 3.0 mL BAC water

BPC Conversion1 unit = 33.3 mcg

TB Conversion1 unit = 33.3 mcg

Weeks 1–2

Starting Phase

BPC-157250 mcg daily = 7.5 units daily

Volume0.075 mL daily

TB-5002 mg, 2x weekly = 60 units each dose

Volume0.60 mL each TB dose

If Drawn Together on TB Day67.5 units total = 0.675 mL

Weeks 3–4

Full Support Phase

BPC-157500 mcg daily = 15 units daily

Volume0.15 mL daily

TB-5002 mg, 2x weekly = 60 units each dose

Volume0.60 mL each TB dose

If Drawn Together on TB Day75 units total = 0.75 mL

Weeks 5–8

Maintenance Framework

BPC-157500 mcg daily = 15 units daily

Volume0.15 mL daily

TB-5002 mg weekly = 60 units once weekly

Volume0.60 mL on TB day

If Drawn Together on TB Day75 units total = 0.75 mL

Injection Strategy
Daily BPC-157 with lower-frequency TB-500 allows each peptide to follow a different research-use schedule rather than forcing both into the same daily frequency.
Why use separate vials?

More Control

This setup keeps BPC-157 on a daily schedule while allowing TB-500 to follow a lower-frequency systemic pattern.

Best For

More flexible and better preserves the different frequency patterns commonly discussed for BPC-157 and TB-500 research-use protocols. Direct human evidence has not established an optimal combined schedule.

How to Use the Wolverine Stack (Cycle, Timing & Injection)

Research-Use Cycle4–8 weeks

Commonly Discussed Break2–4 weeks off

ReassessmentBefore repeating another defined research period

Injection TypeSubcutaneous

Use StyleBlended or separate vials

Best Time to Take

Any consistent time of day can work

Blended version is typically once daily

Separate-vial version often follows daily BPC-157 with less frequent TB-500

Consistency matters more than exact timing

Where to Inject

Abdomen, thigh, or upper arm

Localized BPC-157 injection near a target area is commonly discussed in research-use protocols, but human evidence has not established that local injection provides greater benefit. TB-500 is commonly discussed as a systemic research compound, but standardized human subcutaneous administration guidance has not been established.

You can draw both peptides into one syringe or inject separately depending on preference

Areas of Research Interest

Tendon, ligament, and connective-tissue research

Muscle and soft-tissue repair models

Inflammatory and regenerative-signaling research

Multi-pathway recovery research

Blended versus separate-component research frameworks

Simple Strategy

Blended

Best for simplicity and one-syringe convenience.

Separate

Best for more control over BPC-157 and TB-500 frequency and timing.

Blended vs Separate: Key Differences

Blended Vial

One-syringe convenience

Simpler reconstitution and unit math

Both peptides follow the same dosing frequency

Less flexibility to adjust BPC-157 or TB-500 independently

Separate Vials

Independent control of each peptide

Allows BPC-157 and TB-500 to follow different research-use schedules

More flexibility to adjust dose or frequency independently

Requires separate reconstitution, calculations, and tracking

Key difference:
A blended vial prioritizes simplicity, while separate vials provide more control over the amount and frequency of each component. Neither approach has been established as superior in controlled human clinical trials.

Storage & Shelf Life

Storage & Shelf Life

Lyophilized (unmixed)

Refrigerated (2–8°C): ~12–24 months

Frozen (−20°C): up to ~2–3 years

Reconstituted (mixed)

Refrigerated (2–8°C): ~30 days typical use window

Do not freeze after mixing

Blended vs Separate Storage

Blended Vials

Both peptides share the same solution, so stability is tied together. If one begins degrading, the entire vial is affected.

Separate Vials

Each peptide is stored and managed independently, allowing separate tracking of reconstitution dates and handling.

Best Practice

Handling

Keep vials cold and protected from light.

Temperature

Avoid repeated temperature changes.

Visual Check

If solution becomes cloudy, discolored, or has particles, discard.

Technique

Use clean injection technique to help prevent contamination.

Monitoring During Use

Injection-site tolerance

Changes relevant to the defined tissue-repair or recovery goal

Any new or unexpected symptoms

Overall response to the combined research framework

Benefits

Combines compounds studied across complementary tissue-repair pathways

BPC-157 has demonstrated regenerative and cytoprotective effects primarily in preclinical research

TB-500 is associated with cell-migration and tissue-repair research

The combination is commonly discussed in musculoskeletal recovery research communities

The combined Wolverine Stack has not been validated in controlled human clinical trials

Potential Side Effects

Injection-site irritation, redness, or swelling may occur

Sensitivity reactions are possible

Human safety data for the combined BPC-157 + TB-500 protocol are lacking

Long-term safety of repeated combined use has not been established

Important Notes

The Wolverine Stack combines BPC-157 and TB-500 in a two-compound research-use framework.

No standardized human dose, frequency, cycle length, or maintenance regimen has been established for the combined stack.

Human evidence for BPC-157 remains limited, while direct human evidence for TB-500 is especially sparse.

Blended vials force both peptides to follow the same ratio and frequency, while separate vials allow each component to be adjusted independently.

Evidence for either individual component should not automatically be interpreted as evidence for the safety or effectiveness of the combination.

Important Disclaimer

BPC-157 and TB-500 are investigational compounds and are not FDA-approved. This content is for educational and research purposes only.

Research & References

Primary Research

• Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors: Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design. 2018;24(18):1972-1989.
• Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin Beta4: A Multi-Functional Regenerative Peptide — Basic Properties and Clinical Applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51.
• Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic Potential of Pro-Angiogenic BPC157 Is Associated with VEGFR2 Activation and Up-Regulation. Journal of Molecular Medicine. 2017;95(3):323-333.
• Malinda KM, Sidhu GS, Mani H, et al. Thymosin Beta4 Accelerates Wound Healing. Journal of Investigative Dermatology. 1999;113(3):364-368.

Research Note: Dosing protocols for the Wolverine Stack (BPC-157 + TB-500) are drawn from general peptide-handling practice and preclinical research settings rather than a standardized clinical dosing regimen, since neither compound is FDA-approved for the uses discussed here.

Wolverine Stack Guide → Peptide Directory →